India is finally set to gain the upper hand against the dengue menace that has been silently spreading across the country for decades, striking fear into thousands. India’s drug regulatory authority (CDSCO/DCGI) has granted official approval for the use of “Qdenga” (TAK-003), a vaccine developed by the renowned Japanese pharmaceutical company Takeda Biopharmaceuticals. The arrival of this vaccine marks a crucial turning point in the fight against dengue, which until now has relied solely on mosquito control, early diagnosis, and supportive treatment. Notably, this is the first dengue vaccine to be approved in India.
The severity of the situation is reflected in the fact that nearly one-third of all dengue cases reported worldwide occur in India alone. Over the past two decades, dengue cases in the country have risen nearly 11-fold, with more than a lakh cases reported in 2025 alone. The disease intensifies particularly during the monsoon season, placing severe strain on hospitals. Against this backdrop, clinical trials have shown that the vaccine reduces the risk of hospitalization among patients by as much as 84.1 percent, offering major relief to the public health system.
Qdenga is a tetravalent live-attenuated vaccine that provides protection against all four dengue virus serotypes (DENV 1, 2, 3, and 4) responsible for the disease. It can be administered to anyone between the ages of 4 and 60. The World Health Organization (WHO) has already specifically recommended its use for children aged 6 to 16 in dengue-endemic areas. More than 32 million doses have been distributed worldwide so far, across 43 countries in Asia and beyond.
One of the biggest advantages of this vaccine is that no blood tests are required beforehand to check whether a person has previously had dengue. Anyone can safely take the vaccine regardless of prior testing. It is administered subcutaneously in a dose of 0.5 ml, given as two doses three months apart. The expert committee granted this approval based on Phase-3 clinical trials conducted on the Indian population, along with international research.
To ensure rapid, uninterrupted availability of the vaccine across the country, Takeda has entered into a strategic partnership with the renowned Hyderabad-based company Biological E. Under this agreement, a production capacity of 50 million (5 crore) doses per year will be established in India. This will not only meet the needs of the Indian population but also position India as a major hub for global supply.
However, even though regulatory approval has been granted by the drug controller, the government is yet to clarify several key aspects — including the market price of the vaccine, when it will be included in the national immunization program, which age groups will be prioritized initially, and whether it will be made available free of cost in government hospitals. Regardless, medical experts are describing the approval of the Qdenga vaccine as a historic achievement for India in its fight against dengue.